A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease (CUREPARK)

NCT03899324 Phase 2 UNKNOWN

This is multicentre, proof of concept, randomized, double-blind, parallel-group, placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in 2 groups receiving Bumetanide or placebo for 4 months: * Group 1 (20 PD patients): bumetanide * Group 2 (20 PD patients): placebo intake identically to group 1.

Details

Lead sponsor	B&A Therapeutics
Phase	Phase 2
Status	UNKNOWN
Enrolment	40
Start date	2019-04-26
Completion	2021-08

Conditions

• Parkinson Disease

Interventions

• Bumetanide white, oblong, scored tablet
• Placebo white, oblong, scored tablet

Primary outcomes

• The primary endpoint of this study is the change from baseline (V2) to endpoint (V5) in the MDS-UPDRS III motor score, evaluated 1 hour after the intake of the study treatment (Bumetanide or placebo) in patients in the OFF state. — Between Day 1 and Day 120

Countries

France